COMUNICADO: Croma-Pharma: Further strengthening its portfolio with PhilArt biostimulators

VIENNA, March 30, 2023 /PRNewswire/ -- Croma (Croma-Pharma® GmbH) is a global player and challenger in the dynamically growing, minimally invasive aesthetics market and a leading manufacturer of premium quality hyaluronic acid (HA) syringes.

COMUNICADO: Croma-Pharma: Further strengthening its portfolio with PhilArt biostimulators

VIENNA, March 30, 2023 /PRNewswire/ -- Croma (Croma-Pharma® GmbH) is a global player and challenger in the dynamically growing, minimally invasive aesthetics market and a leading manufacturer of premium quality hyaluronic acid (HA) syringes. With the launch of PhilArt, a complete series of injectable skin boosters, Croma is now further broadening its already comprehensive portfolio. Skin boosters are an important pillar of a minimally invasive aesthetics portfolio, next to HA fillers, botulinum toxin and PDO threads, allowing for combination therapies and a full-face approach. Read More

Contact:Uschi MayerExternal Communications

Logo: https://mma.prnewswire.com/media/2044449...

View original content: https://www.prnewswire.co.uk/news-releases/croma-pharma-further-strengthening-its-portfolio-with-philart-biostimulators-301786087.html

NEXT NEWS